In a previously published study, our multivariate analysis revealed that NLR was the only factor associated with both poor ORR and shorter PFS in melanoma patients treated with anti-PD-1 antibodies, suggesting that NLR is a strong predictive factor for poor outcome in patients treated with ICIs (45). The gene discussed is PDCD1; the disease is melanoma.